Senores Pharmaceuticals reports Rs 664 crore total income for FY26, marking 65% growth

Business Desk — Thu, 14 May 2026 08:58:20 +0000

Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company, has announced its audited financial results for the fourth quarter and full year ended 31st March 2026, showcasing robust financial and operational performance. The company reported a total income of ₹664 crore for FY26, reflecting a significant 65% year-on-year increase.

In the fourth quarter of FY26, Senores Pharmaceuticals achieved a total income of ₹190 crore, marking a 66% increase compared to the same period last year. The company’s EBITDA for Q4FY26 stood at ₹62 crore, a remarkable 219% year-on-year growth, while the Profit After Tax (PAT) was ₹37 crore, up by 104% from the previous year.

The financial year 2026 saw Senores Pharmaceuticals’ EBITDA reaching ₹200 crore, a 114% increase year-on-year, and PAT at ₹122 crore, up by 108% from FY25. The company has also reported a strong improvement in cash flow operations, with cash flow from operations for FY26 at ₹75 crore.

Senores Pharmaceuticals’ regulated markets segment reported a revenue of ₹117.8 crore for Q4FY26, a 169% increase from the previous year. The emerging markets segment grew by 5.7% year-on-year, with revenue reaching ₹49.5 crore. The branded generics segment showed a substantial growth of 132.4% in Q4FY26, with revenue at ₹9.4 crore.

The company has a robust product pipeline for regulated markets, with 51 approved ANDAs covering 151 strengths, and over 30 ANDAs yet to be launched. Additionally, 27 ANDAs are under development with more than 65 strengths.

Senores Pharmaceuticals has also expanded its portfolio through strategic acquisitions, including a 51% membership interest in Zoraya Pharmaceuticals, LLC, and a 75% stake in Apnar Pharmaceuticals, with plans to complete the acquisition by Q2FY27. The company has entered the U.S. federal market via a strategic joint venture, Amerisyn, creating a pathway to supply pharmaceuticals to federal, veterans, and defence sectors.

Managing Director Swapnil Shah commented on the performance, stating that the company has delivered robust performance across segments in FY26, driven by operational discipline and strong momentum in key growth areas. The company remains confident in sustaining this momentum in the years ahead, led by a robust product pipeline and expanded manufacturing capacities.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Zoraya Pharmaceuticals | Business Upturn

Senores Pharmaceuticals reports Rs 664 crore total income for FY26, marking 65% growth